Advanced Solid Tumors Clinical Trials in Scottsdale, Arizona

5 studies are recruiting for advanced solid tumors in Scottsdale, Arizona right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Trial to Investigate the Safety of E303 in Participants With Advanced Refractory Solid Tumors

   This is a Phase I trial to evaluate the safety, tolerability and efficacy of nectin-4 targeting antibody-drug conjugate (SBE303) in participants with advanced solid tumors

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Research Site, Scottsdale, Arizona

   Locations

   7 in total

   Run by

   Samsung Bioepis Co., Ltd.

   See if you can join NCT07524348 on ClinicalTrials.gov

2. A Study to Test the Safety and Tolerability of SBO-154 in Patients With Advanced Solid Tumors.

   This is a Phase 1 study of SBO-154 in patients with advanced cancers who are unable to tolerate or have not previously responded to standard therapy available in the country. The study involves multiple doses and takes place at several centers.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honorhealth Research Institute, Scottsdale, Arizona

   Locations

   16 in total

   Run by

   Sun Pharma Advanced Research Company Limited

   See if you can join NCT07042100 on ClinicalTrials.gov

3. Study of DT-7012 as a Single Agent and in Combination With an Immune Checkpoint Inhibitor in Participants With Advanced Solid Tumors

   This is a phase 1/2, dose-escalation, clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy of DT-7012 (an anti-CCR8 monoclonal antibody) as a single agent and in combination with an immune checkpoint inhibitor in adult participants with selected advan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health Research Institute, Scottsdale, Arizona

   Locations

   9 in total

   Run by

   Domain Therapeutics Australia Pty Ltd

   See if you can join NCT06819735 on ClinicalTrials.gov

4. Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

   The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pharmacokinetics and preliminary antitumor activity.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Honor Health, Scottsdale, Arizona

   Locations

   7 in total

   Run by

   Tagworks Pharmaceuticals BV

   See if you can join NCT06959706 on ClinicalTrials.gov

5. Dose Escalation and Expansion Study Evaluating ODC-IL2 in Adult Patients With Advanced or Metastatic Solid Tumors

   This is a first-in-human, Phase I, multicenter, open-label, dose escalation study with dose expansion to evaluate the safety and antitumor activity of ODC-IL2 in patients with advanced or metastatic solid tumors. ODC-IL2 is a conditionally activated IL-2 prodrug and will be administered as a single…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   HonorHealth, Scottsdale, Arizona

   Run by

   Trutino Biosciences Inc.

   See if you can join NCT06770764 on ClinicalTrials.gov